论文部分内容阅读
目的探讨阿奇霉素序贯治疗肺炎衣原体(CP)肺炎的临床疗效可行性及安全性。方法经血清学检测肺炎衣原体抗体阳性的肺炎60例,随机分为两组各30例,治疗组采用阿奇霉素针10 mg/(kg.d),1次/d静滴,连用3 d后,转换为阿奇霉素颗粒连服3 d,停4 d为一疗程。对照组用红霉素针25~30 mg/(kg.d),1次/d,静滴10 d为一疗程,观察治疗前后患儿症状,肺部体征的变化及不良反应。结果治疗组、对照组总有效率分别为93.3%和86.7%(χ2=0.19,P>0.05),差异无统计学意义,而显效率分别为83.37%和53.3%(χ2=6.24,P<0.05),不良反应分别为6.7%和40.0%(χ2=7.55,P<0.01)差异有统计学意义。结论两组治疗有同样的效果,但显效率、不良反应发生率阿奇霉素明显优于红霉素,值得临床应用。
Objective To investigate the clinical efficacy and safety of sequential treatment of pneumonia with Chlamydia pneumoniae (CP) by azithromycin. Methods Sixty patients with pneumonia chlamydia pneumoniae positive by serological tests were randomly divided into two groups of 30 patients. The patients in the treatment group were given azithromycin 10 mg / (kg · d) once a day for 3 d, Azithromycin granules for 3 d, stop 4 d for a course of treatment. The control group with erythromycin needle 25 ~ 30 mg / (kg.d), 1 / d, intravenous infusion of 10 d for a course of treatment before and after treatment to observe the symptoms of children, changes in lung signs and adverse reactions. Results The total effective rates of the treatment group and the control group were 93.3% and 86.7%, respectively (χ2 = 0.19, P> 0.05), but the difference was not statistically significant, while the effective rates were 83.37% and 53.3% ), Adverse reactions were 6.7% and 40.0% (χ2 = 7.55, P <0.01), the difference was statistically significant. Conclusion The two groups of treatment have the same effect, but the obvious efficiency, the incidence of adverse reactions azithromycin significantly better than erythromycin, worthy of clinical application.